Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Pharmacology, Toxicology and Pharmaceutical Science
37
4%
Other
81
9%
Unknown
231
26%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 107. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 September 2026.
All research outputs
#493,114
of 33,953,699 outputs
Outputs from Lancet Oncology
#637
of 7,940 outputs
Outputs of similar age
#4,717
of 293,527 outputs
Outputs of similar age from Lancet Oncology
#9
of 152 outputs
Altmetric has tracked 33,953,699 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,940 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.5. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 293,527 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 152 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.
